Classical Models of Senile Osteoporosis

Watanabe, Ken

doi:10.1007/978-0-85729-293-3_10

Cited by 2 publications

(1 citation statement)

References 69 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Gou et al (2010) also used SAMP6 mice for investigation the bone loss condition in substituted benzothiophene or benzofuran derivatives. Thus, SAMP6 is useful as senile osteoporosis model (122,123).…”

Section: Chapter V Discussionmentioning

confidence: 99%

Bioactive compounds with an inhibitory activity against osteoclast differentiation and mechanisms

Chawalitpong

View full text Add to dashboard Cite

???????????????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????? (osteoblast) ?????????????????????????????? (osteoclast) ????????????????????????????????????????????????????????????????????? ????????????????????????????? ??? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????????????? (3S)-1-(3,4-dihydroxyphenyl)-3-hydroxy-7-phenyl-(6E)-6-heptene (DHPH) ??? ??????????????? (Cyperenoic acid) ??????????????????????? Curcuma comosa Rox. ?????? Croton crassifolius Geiseler. ???????? ????????????????????????????????????????? ??????? in vitro ???????????????????????????????????? receptor activator of nuclear factor-?B ligand (RANKL) DHPH ?????????????????????????????????????????????????????? ????????????????? TRAP-positive multinucleated cells (TRAP+ MNCs) ??????????????????????????????????? (IC50) 325?1.37 ?????????? ??????????????????????????????????????????????????????????????????? RANKL ????????????? Mitogen-activated protein kinases (MAPKs) ???? ERK (p44/42) ??? p38 ????????????????? NF-?B ??????????????????????????????????????????? transcription factor ???? nuclear factor of activation T cells (NFATc1) ??? c-Fos ????????????????????????????????????????????????????? DHPH ??????????????????? (bone resorption) ???????????? (bone slices) ????????????? DHPH ??????????????????????????????? alkaline phosphatase (ALP) ???????????????????????????????????????????????????????????? MC3T3-E1 ???????????????????????????? ???????????????????? TRAP+ MNCs ??????????????????? IC50 ??? 36.69?1.02 ??????????? ???????????????????????????????????????????????? MAPKs ??? canonical NF-?B? ????????????????????????????????? RANKL ??????????????????????????????????? non-canonical NF-?B ????????????????????????? p100/p52 ??? TRAF3 ????????????????????????????????????????????? NFATc1 ??? c-Fos ???????????????????????????????????????????????????? ???? nfatc1, ctsk ??? irf8 ??????? ???????????????????????????????????????????????????????????????????????????????????? (Dentin slices) ???????????????????????????? in vivo ??????????????????????? Senescence-accelerated mouse prone 6 (SAMP6) ????????????????????????????????????????????????????????? (bone area) ??????????????????????? trabecular (trabecular area) ??????????????????? SAMP6 ???????????????????????????????????????? ibsp ?????????????????????????????? bone sialoprotein ??????????????????????????????????????????????????????????????? ???????????????????????????????????? DHPH ?????????????????? ?????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????????????????? ?

show abstract

Section: Chapter V Discussionmentioning

confidence: 99%

Bioactive compounds with an inhibitory activity against osteoclast differentiation and mechanisms

Chawalitpong

View full text Add to dashboard Cite

show abstract

Animal Models for the Study of Osteoporosis

Abdi

2024

Animal Models in Experimental Medicine

View full text Add to dashboard Cite

Osteoporosis (OP) is a widespread disease characterized by reduced bone mass and disruption of bone microarchitecture. The association of this chronic metabolic condition with increased skeletal fragility and vulnerability to fracture is well-established. Although OP is both preventable and curable, being a clinically silent disease, it goes undetected until it manifests in the form of a fragility fracture. These fractures are associated with significant morbidity and mortality among patients. More than 200 million people worldwide are currently suffering from OP, making this critical disease a major public health concern. Due to ongoing demographic changes, the medical and socioeconomic impact of OP is predicted to increase further. However, to date, the management of OP remains a challenge, which necessitates the need for further research to fully understand its molecular mechanism and to establish novel prevention strategies and more effective treatment approaches. Animal models of OP are used widely as appropriate tools to enhance knowledge about disease etiology as well as to do pre-clinical evaluation of treatment and prevention strategies. This chapter aims to overview the currently available well-established animal models of OP with a focus on the ovariectomized rat model for postmenopausal OP. The information provided may help researchers to select an appropriate model in accordance with their research objective.

show abstract

Classical Models of Senile Osteoporosis

Cited by 2 publications

References 69 publications

Bioactive compounds with an inhibitory activity against osteoclast differentiation and mechanisms

Bioactive compounds with an inhibitory activity against osteoclast differentiation and mechanisms

Animal Models for the Study of Osteoporosis

Contact Info

Product

Resources

About